David has 30 years’ experience in Health and Research finance.
Many years after qualifying as a Registered Nurse in 1980, Liz spent her first years as a qualified nurse in respiratory medicine in secondary care, followed by several years in primary care.
Dave Singh is Professor of Respiratory Pharmacology at the University of Manchester.
David has 30 years’ experience in Health and Research finance.
In 1999 he joined the Medicines Evaluation Unit Ltd as Director of Operations and was instrumental in turning a grant-funded NHS department into a successful Phase I clinical trials unit. He also is a Director and co-founder of MEU Solutions Ltd, a CRO offering clinical trials services to Pharma worldwide.
Previously he held senior finance roles in the NHS, in the areas of Contracting and Management Accounting. He is a member of the Medicines and Healthcare products Regulatory Agency (MHRA) phase 1 stakeholder committee and also helped develop the NHS clinical trials agreement the mCTA.
Many years after qualifying as a Registered Nurse in 1980, Liz spent her first years as a qualified nurse in respiratory medicine in secondary care, followed by several years in primary care.
Since 1995 Liz has worked for The Medicines Evaluation Unit, formerly as a Research Nurse and Study Coordinator involved in the set up, conduct and management of all aspects of clinical trials.
Now with 20 years’ experience in early phase trials, specialising in respiratory, Liz has held a Senior Management role since 2002 and is responsible for assessing protocol feasibility, planning and oversight of trial conduct and ensuring compliance to maintain the MHRA Phase 1 Accreditation.
Dave Singh is Professor of Respiratory Pharmacology at the University of Manchester.
He graduated from Cambridge University and went on to train in medicine and clinical pharmacology in Manchester, which included working in industry on early phase clinical trials. His research interests are in the pharmacotherapy of Asthma and COPD, with studies spanning from basic pharmacology of anti-inflammatory drugs to clinical trials.
He has acted as Principal Investigator on numerous clinical trials of novel therapies in asthma and COPD, and has over 200 publications in peer reviewed journals. He is a member of the GOLD Science Committee.